These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2571616)

  • 1. Alpha-1 blockers. A new generation of antihypertensive agents.
    Humphreys JE; Waite MA
    J Clin Pharm Ther; 1989 Aug; 14(4):263-83. PubMed ID: 2571616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related effects of antihypertensive therapy with alpha-blockers.
    Stokes GS
    J Cardiovasc Pharmacol; 1988; 12 Suppl 8():S109-15. PubMed ID: 2469891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.
    Louis WJ; Drummer OH; Howes LG
    Clin Exp Hypertens A; 1989; 11(5-6):1075-83. PubMed ID: 2571433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.